SCHEDULE: Millennium Management Discloses Stake in Tenax Therapeutics

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported a 3.3% stake in Tenax Therapeutics, Inc.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, indicating their beneficial ownership of Tenax Therapeutics, Inc. common stock.
• The filing reports a total of 876,230 shares beneficially owned, representing 3.3% of the class of securities.
• This filing is an amendment, indicating a change in reporting status or holdings.
• The reporting persons have shared voting and dispositive power over these shares.
• The filing clarifies that the securities are held by entities subject to the voting control and investment discretion of Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership by an investment firm and does not inherently signal positive or negative performance for the company.

Positives

• Disclosure of a significant investment stake by a major investment firm in Tenax Therapeutics.
• The filing indicates shared voting and dispositive power, suggesting a coordinated investment strategy.

Negatives

• The filing does not provide specific details on the timing or rationale behind the acquisition of these shares.
• The disclosure is a Schedule 13G, which is typically filed by passive investors, but the exact nature of the investment (passive vs. active) is not explicitly detailed beyond the certification.

Risks

• Potential for future changes in beneficial ownership, which could impact the stock price.
• The investment by Millennium Management could signal confidence, but also potential for significant selling if their strategy changes.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Tenax Therapeutics. It is a disclosure of beneficial ownership by Millennium Management.

Management Comments

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander confirm that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
• Gil Raviv, Global General Counsel for Millennium Management LLC and Millennium Group Management LLC, certified the accuracy of the filing.
• Israel A. Englander certified the accuracy of the filing.

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by Millennium Management, a prominent hedge fund, in Tenax Therapeutics, Inc. suggests a significant investment interest in the biotechnology sector, which has seen increased activity from institutional investors seeking growth opportunities.

Stakeholder Impact

• Shareholders: May view the investment by a large fund as a positive signal, but also be aware of potential for significant share movement if the fund decides to alter its position.
• Management of Tenax Therapeutics: May see increased scrutiny or potential engagement from a significant institutional investor.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitoring of Tenax Therapeutics, Inc. for any further disclosures or strategic announcements.
• Observation of potential future trading activity by Millennium Management LLC and its affiliates.

Key Dates

Keywords

Tenax Therapeutics, Millennium Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, 3.3%